‘You Can See Everything’ Lands A Metacritic Review Score Record - Forbes

Vancouverites have spent four years governed by Mayor Ken Sim and his ABC-led council that shed members over time. Today voters provide their final grade by saying who they want next for mayor, council, park board and school board. The Tyee has dispatched reporters to several parties’ headquarters and after the polls close at 8 p.m. we’ll be updating this story as details, including results, reveal the end of what has been a long election season with many twists and turns.

Paulo Kawanishi is a Brazilian freelance writer and contributor on Polygon. He's been writings guides, features, and reviews since 2022 for publications like Eurogamer, Game Informer, Nintendo Life, PCGamesN, and Into the Spine. He's part of the guides team at Polygon, working on projects that cover from long explaners to quick tips on how to complete specific tasks in games. In addition, he also writes features, analysis, and reviews especially about JRPGs and games like Path of Exile 2. He holds a master's degree and a Ph. D. in Applied Linguistics. The symbol of older, more exciting times

Today is a day of not one, but more than 200 different elections. In 161 municipalities, 27 regional districts and 60 school districts, British Columbians will elect new representatives to govern the institutions that shape everyday life.

Bioengineer.org news storyFor millions of people living with HIV, antiretroviral therapy has transformed a once-fatal infection into a manageable chronic condition. Yet the very drugs that suppress the virus can carry quiet costs, and one of the most insidious is bone loss. Tenofovir disoproxil fumarate, or TDF, has been a cornerstone of HIV treatment worldwide for two decades, prized for its potency, durability, and low cost. But a growing body of evidence has linked TDF exposure to measurable reductions in bone mineral density, raising an increasingly urgent clinical question: once bone has been lost on a TDF-based regimen, can it be recovered? A new prospective cohort study, published in BMC Infectious Diseases, offers some of the most detailed longitudinal evidence to date that the answer, for many patients, is yes. The research team enrolled 223 virologically suppressed men living with HIV who had low bone mineral density while taking TDF-based antiretroviral therapy.